Form 4: Neurocrine Biosciences Director Exercises Stock Options and Disposes of Shares
SEC Form 4 Filing
Director Gary A. Lyons exercised stock options and disposed of 2,100 shares of Neurocrine Biosciences common stock on May 17, 2024.
Summary
- On May 17, 2024, Gary A. Lyons, a director of Neurocrine Biosciences Inc., exercised restricted stock units (RSUs) and disposed of the underlying shares.
- Lyons exercised RSUs representing 2,100 shares of common stock.
- The transaction resulted in the disposal of 2,100 shares at a price of $0.
- Following the transaction, Lyons directly owns 119,047 shares, with 110,964 of those shares held in a revocable living trust.
Sentiment
Score: 5
Explanation: This is a neutral event. It's a standard disclosure of a director exercising stock options and selling shares, which doesn't inherently indicate positive or negative sentiment about the company's future.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, trade in their company's stock; this provides transparency to the market.
Stakeholder Impact
- The transaction has a minimal impact on stakeholders as it represents a routine insider transaction.
Key Dates
| Date | Description |
|---|---|
| 06/08/2012 | Date of Gary A. Lyons Revocable Living Trust U/A |
| 05/17/2023 | Date the RSU award was granted to the Reporting Person and is fully vested. |
| 05/17/2024 | Date of transaction: exercise of restricted stock units and disposal of shares. |
| 05/21/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.